ORECORP LTD(ORR.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

ORR.AU ORECORP LTD

Market Closed 12-19 16:00:00 AEDT

0.57

+0.00

0.00%

High0.57	Low0.57	Vol0.00
Open0.57	D1 Closing0.57	Amplitude0.00%
Mkt Cap267.48M	Tradable Cap56.81K	Total Shares473.42M
T/O0.00	T/O Rate0.00%	Tradable Shares100.55K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORR.AU","market":"AU","secType":"STK","nameCN":"ORECORP LTD","latestPrice":0.565,"timestamp":1766120400000,"preClose":0.565,"halted":0,"volume":0,"delay":0,"nameEN":"ORECORP LTD","floatShares":100554,"shares":473420998,"eps":-0.107822,"marketStatus":"Market Closed","change":0,"latestTime":"12-19 16:00:00 AEDT","open":0.565,"high":0.565,"low":0.565,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.107822,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1766358000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.565,"openAndCloseTimeList":[[1766098800000,1766120400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/ORR.AU/wiki","defaultTab":"wiki","newsList":[{"id":"2589802971","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802971","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802971?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients.Results from 501 participants who self-identified as Asian in the MARIPOSA trial, showed those treated with amivantamab plus lazertinib had a 26 percent lower risk of death compared with osimertinib , based on a median follow-up of 38.7 months. MedianOSfor the combination was not yet reached compared with 38.4months for osimertinib . Survival projections suggest that amivantamab plus lazertinib could extend median OS to more than a year beyond that achieved with osimertinib. At three years, 61 percent of patients treated with the combination were alive compared with 53 percent of those receiving osimertinib. The survival advantage was maintained at 42 months, with survival rates of 59 percent and 46 percent,respec","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-delivers-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-benefit-for-asian-patients-with-egfr-mutated-non-small-cell-lung-cancer-in-the--302633939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0466842654.USD","LU0203347892.USD","JNJ","BK4550","LU0345770308.USD","BK7095","LU1674673691.USD","LU2089984988.USD","ORR.AU","LU0234572021.USD","LU1074936037.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","LU1066051225.USD","IE00B3PB1722.GBP","LU1894683348.USD","LU1162221912.USD","LU2505996509.AUD","LU0098860793.USD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU1732799900.SGD","LU2468319806.SGD","LU2129689514.USD","BK4581","BK4534","BK4504","LU0345770993.USD","IE00B3T34201.USD","LU2129689431.USD","LU2505996681.GBP","LU2592432038.USD","IE00BGHQF631.EUR","IE00B4R5TH58.HKD","LU1261432733.SGD","SEER","IE00B1BXHZ80.USD","LU1929549753.HKD","BK4195","IE00B19Z3581.USD","LU1778281490.HKD","BK4559","ORR","OS","PFS","LU0345769631.USD","LU0912757837.SGD","LU1267930813.SGD","LU2602419157.SGD","BK4585"],"gpt_icon":0},{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","ADC.AU","BK4006","BK4231","ORR","BK4181","IE00B19Z4B17.USD","IND.AU","PK","IE0031619046.USD","LU2065731478.USD","ADC","BK4187","CRS.AU","IND","BK4080","IE00B66KJ199.SGD","CRS","ORR.AU","IE00B7SZL793.SGD","BK4218","BK7095"],"gpt_icon":0},{"id":"2586782177","title":"Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782177","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782177?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:52","pubTimestamp":1764334320,"startTime":"0","endTime":"0","summary":"BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd.  announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel  , has received new drug marketing approvalfrom the China National Medical Products Administration . This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma  after two or more lines of systemic therapy. This is the second approved indicationin China for Ina-cel, following its initial approval in November 2023 for the treatment of adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia . This milestone marks the first proprietary CD19 CAR-T product in China with full intellectual property rights to become the only CAR-T cell therapy product in the country that covers both leukemia and lymphoma, the two major hematological oncology indications.Professor Dehui Zou, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences :","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/inaticabtagene-autoleucel-yorwidatm-new-drug-application-for-lymphoma-approved-chinas-innovative-car-t-enters-a-new-era-of-dual-indications-302628059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","IE00B19Z4B17.USD","BK7095","IE00B7SZL793.SGD","CAR","ORR.AU","BK4161","LU2065731478.USD","IE0031619046.USD","BK4022","ORR","IE00B66KJ199.SGD","CR","CRS.AU","BK4230","BK4187","CRS","LU0963586101.USD"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR.AU","BK4110","ACR","IND.AU","CRS","ORR.AU","IE00B66KJ199.SGD","IE0031619046.USD","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK7096","LU2065731478.USD","BK4187","PRGS","LU2065732104.USD","BK4097","CR","BK7095","LU0963586101.USD","BK4161","ORR","BK4006","CRS.AU","BK7508"],"gpt_icon":0},{"id":"2582101208","title":"Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2582101208","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582101208?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:01","pubTimestamp":1762740060,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology  was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association , the Tengchong Science Forum Organizing Committee Office, the World Association for Integrative Oncology , and the China Institute for Integrative Medicine Development Strategy. Academicians, experts, and scholars from across the nation gathered to focus on innovations in cancer diagnosis and treatment while sharing scientific breakthroughs. At the conference, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  presented results from multiple clinical studies on its TROP2 ADC sacituzumab tirumotecan as oral presentations.On November 8, Professor Fang Wenfeng from the Cancer Center of Sun Yat-sen University delivered an oral presentation at the conference on preliminary results from a Phase II study evaluating sac-TMT in treating locally advanced or metasta","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presented-trop2-adc-sacituzumab-tirumotecan-results-from-multiple-clinical-studies-at-the-2025-cchio-congress-302609625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721429402.USD","SG9999015341.SGD","LU1917777945.USD","IE00BFTCPJ56.SGD","BK4007","ADC","LU0203347892.USD","LU2468319806.SGD","SG9999013999.USD","BK4533","LU2148510915.USD","ORR","ORR.AU","DAR","LU1699723380.USD","MRK","LU1037948541.HKD","IE00BSNM7G36.USD","LU2361044865.SGD","LU0238689110.USD","PR","LU1934455277.USD","BK4189","SG9999014567.USD","LU0234572021.USD","LU2461242641.AUD","LU0965509010.AUD","LU1934455194.USD","LU2023250843.SGD","PFS","002422","BK4588","BK4534","LU1162221912.USD","LU1989772923.USD","LU2023250504.SGD","EC","LU1934453819.USD","LU0106261612.USD","LU1941712348.USD","LU0265550946.USD","LU1066053197.SGD","BC","LU1291159041.SGD","LU1989772840.SGD","MSD","LU2361044949.HKD","SG9999014542.SGD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2576833639","title":"ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2576833639","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576833639?lang=en_us&edition=fundamental","pubTime":"2025-10-20 14:58","pubTimestamp":1760943480,"startTime":"0","endTime":"0","summary":"BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology  Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma  sponsored by RemeGen Co., Ltd. was presented at the Presidential Symposium by Professor Jun Guo from Beijing Cancer Hospital. It's the first time a research led by Chinese scholars in the field of urological oncology has ever been selected in this honorable session. The full manuscript was simultaneously published online in The New England Journal of Medicine . This marks the first time that the results of a Chinese evidence-based medical research in the field of urothelial carcinoma have been recognized by both an authoritative international academic conference and a top-tier journal.The results showed that the RC48-C016 study met the dual primary endpoints of Progression-Free Survival  and Overall Survival .","market":"other","thumbnail":"https://mma.prnewswire.com/media/1986829/RemiGen_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1986829/RemiGen_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/esmo-congress-2025-presidential-symposium-oral-presentation--disitamab-vedotin-achieves-major-breakthrough-as-first-line-treatment-for-urothelial-carcinoma-302588770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK7095","OS","ORR","ORR.AU","BK4097","BK4211","PFS"],"gpt_icon":0},{"id":"2576000976","title":"Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2576000976","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576000976?lang=en_us&edition=fundamental","pubTime":"2025-10-20 09:00","pubTimestamp":1760922000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forhematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 , were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025  in Berlin, Germany.Details of the Poster Presentation: ATG-022 Title:Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer Abstract Number: 2907Presentation Number: 2113P. ATG-022 is a CLDN18.2-targeted ADC with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload , ATG-022 has demonstrated potent activity across tumors with high, low, and ultra-low CLDN18.2 expression.AmongGC/GEJC patients with low/ultra low CLDN18.2 expressi","market":"other","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-latest-atg-022-clinical-data-at-esmo-2025-demonstrating-efficacy-across-all-cldn18-2-expression-levels-and-exceptional-tolerability-302588393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","BK4161","CRS","CR","OS","LU2065731478.USD","ORR.AU","IND.AU","IE00B19Z4B17.USD","BK7095","CRS.AU","IE00B7SZL793.SGD","BK4097","LU0963586101.USD","IE00B66KJ199.SGD","BK4187","BK4006","ORR"],"gpt_icon":0},{"id":"2576017886","title":"A Fresh Look at Arcus Biosciences (RCUS) Valuation Following Recent Stock Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2576017886","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576017886?lang=en_us&edition=fundamental","pubTime":"2025-10-20 08:23","pubTimestamp":1760919830,"startTime":"0","endTime":"0","summary":"Arcus Biosciences (RCUS) has caught the attention of investors after a steady rally, with shares climbing 37% over the past month. The company’s performance stands out compared to broader sector trends, sparking fresh discussions around its growth story.\nSee our latest analysis for Arcus Biosciences.\nLooking beyond this month’s surge, Arcus Biosciences’ share price has made a dramatic 80% jump in the past 90 days, signaling growing investor optimism. However, its total shareholder return over...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rcus/arcus-biosciences/news/a-fresh-look-at-arcus-biosciences-rcus-valuation-following-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rcus/arcus-biosciences/news/a-fresh-look-at-arcus-biosciences-rcus-valuation-following-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7095","ORR","RCUS","BK4195","BK4139","PFS","ORR.AU"],"gpt_icon":0},{"id":"2576009704","title":"Immutep Says Combination Therapy Generated Strong Objective Response, Disease Control Rates in Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2576009704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576009704?lang=en_us&edition=fundamental","pubTime":"2025-10-20 06:25","pubTimestamp":1760912740,"startTime":"0","endTime":"0","summary":"Immutep  said the combination of its eftilagimod alfa drug candidate with Merck's anti-PD-1 therapy Keytruda and chemotherapy generated strong objective response rates  and disease control rates  in 51 evaluable patients with advanced or metastatic non-squamous non-small cell lung cancer, according to a Monday filing with the Australian bourse.Based on data from the Insight-003 trial, the combination therapy achieved a nearly 62% ORR in 47 patients, up from the historical control of about 41%, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BN8TJ469.HKD","LU1941712264.USD","LU1069347547.HKD","LU1057294990.SGD","SG9999015341.SGD","BK4534","IE00B4R5TH58.HKD","LU1699723380.USD","BK4516","ORR.AU","IE00BJT1NW94.SGD","SG9999001440.SGD","LU0208291251.USD","SG9999014542.SGD","LU1162221912.USD","LU0265550359.USD","LU1934455863.HKD","LU0006306889.USD","SG9999014567.USD","IE0002141913.USD","SG9999002232.USD","IE00BJJMRZ35.SGD","LU0203347892.USD","BK7067","LU1066053197.SGD","LU0098860793.USD","MRK","LU0266013472.USD","ORR","BK4533","LU1989772923.USD","IE00B1BXHZ80.USD","BK7095","SG9999014559.SGD","LU1571399168.USD","IE00BLSP4239.USD","SG9999015358.SGD","LU0965509010.AUD","BK7508","SG9999013999.USD","SGXZ57979304.SGD","LU1061106388.HKD","IMM.AU","BK4559","LU1934455277.USD","LU1585245621.USD","LU2468319806.SGD","LU2361044949.HKD","LU2112291526.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2576102255","title":"Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2576102255","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576102255?lang=en_us&edition=fundamental","pubTime":"2025-10-19 15:00","pubTimestamp":1760857200,"startTime":"0","endTime":"0","summary":"AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design. AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs. Promising antitumor activity was observed in heavily pretreated patients with melanoma and gynecologic cancers without MUC18 preselection. SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicenter dose escalation and expansion study evaluating AMT-253, a MUC18-directed antibody-drug-conjugate , in patients with melanoma and other advanced solid tumors. The data are being presented on October 19th at the 2025 European Society for Medical Oncology  Annual Meeting being held in Berlin, Germany.\"We are excited by the durable antitumor activity observed in the early clinical results of AMT-253, part","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/multitude-therapeutics-announces-encouraging-interim-phase-iii-results-from-ongoing-first-in-human-study-evaluating-its-muc18-directed-antibody-drug-conjugate-amt-253-in-melanoma-and-other-advanced-solid-tumors-at-the-2025-esmo-302588338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK7095","AMT","BK4007","LENZ","BK4533","BK4534","BK4567","BK4585","BK4588","LU0347712357.USD","IE00BFXG0V08.USD","LU2211817866.USD","LU1721428933.USD","LU2413666699.HKD","LU1093756168.USD","ORR.AU","BK4581","BK4121","BK4139","IE00BYQQ9H92.USD","BK4539","BK4231","BK4548","BK4554","BK4080","ADC","ORR","MTD","LU1093756325.SGD","BK4084","LU2413666426.HKD","BK4219"],"gpt_icon":0},{"id":"2574544909","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2574544909","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574544909?lang=en_us&edition=fundamental","pubTime":"2025-10-09 07:40","pubTimestamp":1759966828,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Winchester Energy (ASX:WEL)Winchester Energy started drilling the JVU-5 production we","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7104","ORR","TAR.AU","BK7142","WEL.AU","ATX.AU","BK7095","ORR.AU","CWX.AU","AM5.AU"],"gpt_icon":0},{"id":"2568467974","title":"Imugene Says Drug Candidate Trial in Blood Cancer Patients Achieves 81% Overall Response Rate; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568467974","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568467974?lang=en_us&edition=fundamental","pubTime":"2025-09-18 08:58","pubTimestamp":1758157126,"startTime":"0","endTime":"0","summary":"Imugene  said its Phase 1b clinical trial evaluating drug candidate azer-cel  in patients with blood cancer achieved an overall response rate  of 81%, up from an ORR of 79% in August, according to a Thursday filing with the Australian bourse.Thirteen out of sixteen patients showed a response to the treatment, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7095","ORR","ORR.AU","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2566947754","title":"Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig","url":"https://stock-news.laohu8.com/highlight/detail?id=2566947754","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566947754?lang=en_us&edition=fundamental","pubTime":"2025-09-12 12:39","pubTimestamp":1757651940,"startTime":"0","endTime":"0","summary":"NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing LeadsBiolabs Co., Ltd.  today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial  evaluating Opamtistomig  as monotherapy or in combination with other agents for the first-line treatment of advanced melanoma.Opamtistomig, a uniquely designed PD-L1/4-1BB bispecific antibody that simultaneously blocks PD-1/L1-mediated immune suppression and enhances 4-1BB-regulated T-cell activation. This dual mechanism has the potential to convert \"cold tumors\" into \"hot tumors\", overcoming resistance to immunotherapy and improving response rates in hard-to-treat cancers.In two prior clinical trials, Opamtistomig demonstrated promising efficacy and a favorable safety profile in patients with highly malignant, immune-cold extrapulmonary neuroendocrine carcinoma , both as monotherapy and in combination with chemotherapy. Notably, patient enrollment was completed in August 2025 for a pivotal single-arm registration ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/indication-expansion-accelerates-first-patient-dosed-in-melanoma-phase-1bii-trial-of-opamtistomig-302554832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360108059.USD","IE00B3CCJ633.GBP","LU2023250504.SGD","LU2048586759.USD","ORR.AU","BK4183","IE00BGHQF417.EUR","LU1974910355.USD","HCC","BTC.AU","BK4086","BTC","LU2106854487.HKD","IE0009354923.USD","PFS","LU1917777945.USD","BK7095","ODD","BK4195","BK4211","IE00B2PGVK34.USD","LU2092937221.SGD","LU2041044095.USD","OC","LU2023250843.SGD","LU0868494617.USD","ORR","LU2298321311.HKD","BK4006"],"gpt_icon":0},{"id":"2566944798","title":"Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2566944798","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566944798?lang=en_us&edition=fundamental","pubTime":"2025-09-12 11:00","pubTimestamp":1757646000,"startTime":"0","endTime":"0","summary":"Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more than one year. First and only chemotherapy-free combination in the first line setting to show survival improvement of this magnitude in a population with the highest-prevalence of EGFR-mutated lung cancer. \"Overall survival is the most meaningful measure of progress, and the MARIPOSA Asia cohort results reinforce the role of therapeutic innovations like amivantamab plus lazertinib in the first-line setting,\" said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific. \"With its triple mode of action targeting EGFR a","market":"other","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/asia-cohort-of-phase-3-mariposa-study-shows-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-achieved-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-versus-osimertinib-in-egfr-mutated--302554655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0203345920.USD","LU2471134879.HKD","LU1732800096.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","IE0002141913.USD","LU1162221912.USD","LU1280957306.USD","ORR","SEER","IE00B4R5TH58.HKD","LU0345769631.USD","JNJ","BK4550","LU0320765646.SGD","LU0640476718.USD","LU1032466523.USD","LU1267930813.SGD","LU0289739699.SGD","ORR.AU","LU1061106388.HKD","IE00BVYPNV92.GBP","LU1221951129.SGD","BK4592","IE00BBT3K403.USD","LU2133065610.SGD","LU1718418525.SGD","PFS","LU1066051498.USD","LU2129689605.HKD","IE00BJT1NW94.SGD","BK4121","LU1894683348.USD","LU2129689431.USD","LU0985320562.USD","LU2430703178.SGD","IE0002270589.USD","LU0058720904.USD","LU1244550221.USD","IE00BFTCPJ56.SGD","LU1261432733.SGD","OS","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","IE00B42XCP33.USD","BK4585","LU0345769128.USD","IE000M9KFDE8.USD","BK4195"],"gpt_icon":0},{"id":"2566949975","title":"The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2566949975","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566949975?lang=en_us&edition=fundamental","pubTime":"2025-09-12 09:51","pubTimestamp":1757641860,"startTime":"0","endTime":"0","summary":"SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology  announced that the New Drug Application  for anbenitamab injection , independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. , has been accepted by the National Medical Products Administration . KN026 has been applied for as a Class 1 therapeutic biological product and the indication is for use in combination with chemotherapy for the treatment of patients with HER2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction cancer who have failed at least one prior systemic therapy .Currently, there are no approved anti-HER2 therapies for the second-line treatment of HER2-positive gastric cancer. KN026 is the first HER2 bispecific antibody to demonstrate positive results in the second-line treatment of gastric cancer in China. Meanwhile, multiple pivotal Phase III clinical studies of KN026 in g","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/the-new-drug-application-for-kn026-anbenitamab-injection-has-been-accepted-by-the-national-medical-products-administration-302554598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223083913.SGD","L","BK4017","PFS","ORR.AU","BK4107","BK7095","LU1223082519.USD","BK4195","BK4190","BK4211","BK4585","BC","CDE","LU1223082196.USD","BK4588","BK4097","CDE.AU","NHLD","LU2487616109.SGD","LU0053666078.USD","ORR","BK7050","OS","LU0210528500.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.orecorp.com.au","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0281},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.0935},{"period":"1year","weight":0.2415},{"period":"ytd","weight":0.2485}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"OreCorp Limited operates as a mineral exploration company. The company explores for gold, nickel, copper, cobalt, and precious metals. Its principal properties include the Nyanzaga gold project comprising 20 contiguous prospecting licenses and 2 applications covering an area of 211 square kilometers located in northwest Tanzania, east Africa; the Hobbes gold project covering an area of 93 square kilometers located to the northeast of Kalgoorlie, Western Australia; and the Akjoujt South project consisting of 3 licenses covering 596 square kilometers in northwest Mauritania. The company was incorporated in 2011 and is based in Subiaco, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.023285},{"month":2,"riseRate":0.545455,"avgChangeRate":0.055279},{"month":3,"riseRate":0.5,"avgChangeRate":0.047626},{"month":4,"riseRate":0.25,"avgChangeRate":-0.077912},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.046006},{"month":6,"riseRate":0.636364,"avgChangeRate":0.114909},{"month":7,"riseRate":0.545455,"avgChangeRate":0.060649},{"month":8,"riseRate":0.181818,"avgChangeRate":0.023852},{"month":9,"riseRate":0.454545,"avgChangeRate":0.008437},{"month":10,"riseRate":0.454545,"avgChangeRate":0.064429},{"month":11,"riseRate":0.363636,"avgChangeRate":0.043857},{"month":12,"riseRate":0.545455,"avgChangeRate":0.0265}],"exchange":"ASX","name":"ORECORP LTD","nameEN":"ORECORP LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ORECORP LTD(ORR.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ORECORP LTD(ORR.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ORECORP LTD,ORR.AU,ORECORP LTD股票,ORECORP LTD股票老虎,ORECORP LTD股票老虎国际,ORECORP LTD行情,ORECORP LTD股票行情,ORECORP LTD股价,ORECORP LTD股市,ORECORP LTD股票价格,ORECORP LTD股票交易,ORECORP LTD股票购买,ORECORP LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ORECORP LTD(ORR.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ORECORP LTD(ORR.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction